At the same time, BH3 mimetics, including drugs directed against the anti-apoptotic factors BCL2 and MCL1, represent an attractive class of inhibitors in SCLC but it remains unclear which molecular factors prime susceptibility to these targets10. The gene discussed is BCL2; the disease is small cell lung carcinoma.